JAK/TYK2
Olga Petryna DrPetryna
3 years 11 months ago
@RheumNow #acr21 abst 195 prospective study of JAKi for refractory Still’s in 7 pts suggests JAKs can be useful as an add on but not in monotherapy : partial response 57%& failure in43%. No patient achieved complete remission. steroids could be decreased by63%~ https://t.co/rYHVReRHvL
Tanmayee Bichile, MD BichileT
3 years 11 months ago
The evolving JAK inhibitor story
Black box Warnings regarding JAK inhibitor use and MACE, malignancy, thrombosis and mortality - full safety data remains to be examined.
@ACRheum #ACRambassador #ACR21 https://t.co/imQ1LSxeXM
EnvisionRheumat ERheumat
3 years 11 months ago
#ACR21 #ACR2021
Rheumatology Reproductive Health
👉🏻 Biologics and breast milk
👉🏻 Good vaccine response with TNFi (like with covid vaccines )
👉🏻 ustekimumab seems safe in pregnancy
👉🏻 Tofacitinib/ small molecules may cross placenta/ be in breast milk ➡️ contraindicated in preg/BF https://t.co/qk3sLR4QHz
Dr. Antoni Chan synovialjoints
3 years 11 months ago
New treatments in #psoriaticarthritis Brepocitinib TYK 2/JAK 1 inhibitor had superior efficacy vs PBO in active PsA at Week 16, with improvements in more refractory domains over 52 weeks. Safety consistent with other JAKi @RheumNow #ACR21 Abstr#0488 https://t.co/ugsV7uRwro
Akhil Sood MD AkhilSoodMD
3 years 11 months ago
Abs 0463 #ACR21 @RheumNow
Park & colleagues compared treatment persistence across abatacept, TNFi, and JAKi in dual seropositive RA patients using Medicare database
- Users of abatacept were more persistent to index time of 12 months and showed longer time to discontinuation https://t.co/0huE7zZjLq
Dr. Antoni Chan synovialjoints
3 years 11 months ago
New treatments in #psoriaticarthritis Deucravacitinib TYK2 inhibitor selectively mediates cytokine signaling, specific inflammatory pathways (eg, IL-23, IL-12, and Type I interferons) concomitant with clinical symptom improvement @RheumNow #ACR21 Abst#0490 https://t.co/7JZGa5R4eC
Janet Pope Janetbirdope
3 years 11 months ago
#ClinicalPearl What lasts longer/⬆️retention in sero+ RA: Abatacept or TNFi or JAKi? #ACR21 abst#0463 @RheumNow Adjusting for confounding incl line of Rx / past bio Rx, #abatacept wins. But data not stratified for bio naive or exposed. Not sure if that would alter results https://t.co/1dEQncwPQF
Dr. Rachel Tate uptoTate
3 years 11 months ago
Retrospective French study found adding JAKi may be helpful in refractory AOSD. No complete response noted and no beneficial effect as monotherapy. Possible difference between JAKi? Abs 0195 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/J8kLJpJ39o https://t.co/aVsfCQ8CyV
Robert B Chao, MD doctorRBC
3 years 11 months ago
Gender differences in AS pts?
IL-23R, IL-12R, IL-6R, JAK, STAT and TYK2 ⬇️regulated in men
Small study of 20 pts, but could it guide targeted therapy based on gender?🤔
Abs#0050
https://t.co/OQHQCCzfuC
#ACR21
@RheumNow
Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections. Over the past decade, an armamentarium of biologic and targeted therapies has led to better control of disease activity in patients with rheumatoid arthritis. Whether these patients, especially those receiving newer biological and targeted therapies such as JAK inhibitors, are at an increased risk of severe COVID-19
Eric Dein ericdeinmd
3 years 11 months ago
Year in Review #ACR21. How do you feel about JAK inhibitor after one year of new studies and the new FDA warning? @Rheumnow
Janet Pope Janetbirdope
3 years 11 months ago
#ClinicalPearl #JAKi works in #ankylosingspondylitis (AS). Trial of #tofacitinib positive. Don’t confuse with jack ass! @YearinReview #ACR21 @RheumNow presented by Karen Costenbader https://t.co/2VvEMhiI8L
Poster Hall